ID   GPKOW_HUMAN             Reviewed;         476 AA.
AC   Q92917; Q59EK5; Q9BQA8;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   06-MAR-2007, sequence version 2.
DT   07-APR-2021, entry version 156.
DE   RecName: Full=G-patch domain and KOW motifs-containing protein;
DE   AltName: Full=G-patch domain-containing protein 5;
DE   AltName: Full=Protein MOS2 homolog;
DE   AltName: Full=Protein T54;
GN   Name=GPKOW; Synonyms=GPATC5, GPATCH5, T54;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8938429; DOI=10.1101/gr.6.11.1056;
RA   Schindelhauer D., Hellebrand H., Grimm L., Bader I., Meitinger T.,
RA   Wehnert M., Ross M., Meindl A.;
RT   "Long-range map of a 3.5-Mb region in Xp11.23-22 with a sequence-ready map
RT   from a 1.1-Mb gene-rich interval.";
RL   Genome Res. 6:1056-1069(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-476.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   IDENTIFICATION.
RX   PubMed=16271871; DOI=10.1016/j.cub.2005.09.038;
RA   Zhang Y., Cheng Y.T., Bi D., Palma K., Li X.;
RT   "MOS2, a protein containing G-patch and KOW motifs, is essential for innate
RT   immunity in Arabidopsis thaliana.";
RL   Curr. Biol. 15:1936-1942(2005).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [6]
RP   INTERACTION WITH PRKX.
RX   PubMed=16491121; DOI=10.1038/sj.onc.1209436;
RA   Glesne D., Huberman E.;
RT   "Smad6 is a protein kinase X phosphorylation substrate and is required for
RT   HL-60 cell differentiation.";
RL   Oncogene 25:4086-4098(2006).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-42 AND THR-216, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-216, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-42 AND THR-216, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION AT SER-27 AND THR-316, MUTAGENESIS OF SER-27 AND THR-316,
RP   INTERACTION WITH PRKACB, AND SUBCELLULAR LOCATION.
RX   PubMed=21880142; DOI=10.1186/1750-2187-6-10;
RA   Aksaas A.K., Larsen A.C., Rogne M., Rosendal K., Kvissel A.K.,
RA   Skaalhegg B.S.;
RT   "G-patch domain and KOW motifs-containing protein, GPKOW; a nuclear RNA-
RT   binding protein regulated by protein kinase A.";
RL   J. Mol. Signal. 6:10-10(2011).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-35; SER-42 AND SER-115, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH DHX16, AND MUTAGENESIS OF
RP   176-GLY--TRP-177 AND 259-GLY--LYS-260.
RX   PubMed=25296192; DOI=10.1042/bsr20140142;
RA   Zang S., Lin T.Y., Chen X., Gencheva M., Newo A.N., Yang L., Rossi D.,
RA   Hu J., Lin S.B., Huang A., Lin R.J.;
RT   "GPKOW is essential for pre-mRNA splicing in vitro and suppresses splicing
RT   defect caused by dominant-negative DHX16 mutation in vivo.";
RL   Biosci. Rep. 34:E00163-E00163(2014).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-216; SER-471 AND THR-473, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-5, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: RNA-binding protein involved in pre-mRNA splicing.
CC       {ECO:0000269|PubMed:25296192}.
CC   -!- SUBUNIT: Interacts with PRKX (PubMed:16491121). Interacts with DHX16
CC       (PubMed:25296192). Interacts with PRKACB (PubMed:21880142).
CC       {ECO:0000269|PubMed:16491121, ECO:0000269|PubMed:21880142,
CC       ECO:0000269|PubMed:25296192}.
CC   -!- INTERACTION:
CC       Q92917; Q9P291: ARMCX1; NbExp=3; IntAct=EBI-746309, EBI-2843626;
CC       Q92917; Q9BRD0: BUD13; NbExp=12; IntAct=EBI-746309, EBI-2561235;
CC       Q92917; Q2TAC2: CCDC57; NbExp=3; IntAct=EBI-746309, EBI-2808286;
CC       Q92917; Q6P9H4: CNKSR3; NbExp=3; IntAct=EBI-746309, EBI-10253274;
CC       Q92917; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-746309, EBI-742054;
CC       Q92917; O60231: DHX16; NbExp=3; IntAct=EBI-746309, EBI-311446;
CC       Q92917; Q92620: DHX38; NbExp=2; IntAct=EBI-746309, EBI-1043041;
CC       Q92917; Q5JST6: EFHC2; NbExp=3; IntAct=EBI-746309, EBI-2349927;
CC       Q92917; Q96IJ6: GMPPA; NbExp=3; IntAct=EBI-746309, EBI-750953;
CC       Q92917; Q08379: GOLGA2; NbExp=9; IntAct=EBI-746309, EBI-618309;
CC       Q92917; P46439: GSTM5; NbExp=3; IntAct=EBI-746309, EBI-4312072;
CC       Q92917; Q96ED9-2: HOOK2; NbExp=3; IntAct=EBI-746309, EBI-10961706;
CC       Q92917; O75031: HSF2BP; NbExp=3; IntAct=EBI-746309, EBI-7116203;
CC       Q92917; Q9Y6K9: IKBKG; NbExp=3; IntAct=EBI-746309, EBI-81279;
CC       Q92917; Q63ZY3: KANK2; NbExp=3; IntAct=EBI-746309, EBI-2556193;
CC       Q92917; Q8TBB1: LNX1; NbExp=5; IntAct=EBI-746309, EBI-739832;
CC       Q92917; Q9P2M1: LRP2BP; NbExp=3; IntAct=EBI-746309, EBI-18273118;
CC       Q92917; Q9Y250: LZTS1; NbExp=3; IntAct=EBI-746309, EBI-1216080;
CC       Q92917; Q9Y6D9: MAD1L1; NbExp=3; IntAct=EBI-746309, EBI-742610;
CC       Q92917; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-746309, EBI-16439278;
CC       Q92917; Q14696: MESD; NbExp=3; IntAct=EBI-746309, EBI-6165891;
CC       Q92917; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-746309, EBI-10172526;
CC       Q92917; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-746309, EBI-11522433;
CC       Q92917; O43189: PHF1; NbExp=3; IntAct=EBI-746309, EBI-530034;
CC       Q92917; Q4G0R1: PIBF1; NbExp=3; IntAct=EBI-746309, EBI-14066006;
CC       Q92917; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-746309, EBI-79165;
CC       Q92917; P62487: POLR2G; NbExp=3; IntAct=EBI-746309, EBI-347928;
CC       Q92917; P22694-2: PRKACB; NbExp=4; IntAct=EBI-746309, EBI-5258763;
CC       Q92917; P31321: PRKAR1B; NbExp=3; IntAct=EBI-746309, EBI-2805516;
CC       Q92917; P51817: PRKX; NbExp=2; IntAct=EBI-746309, EBI-4302903;
CC       Q92917; O43172: PRPF4; NbExp=2; IntAct=EBI-746309, EBI-718395;
CC       Q92917; Q6P2Q9: PRPF8; NbExp=2; IntAct=EBI-746309, EBI-538479;
CC       Q92917; P98175: RBM10; NbExp=2; IntAct=EBI-746309, EBI-721525;
CC       Q92917; Q04864-2: REL; NbExp=3; IntAct=EBI-746309, EBI-10829018;
CC       Q92917; Q9HAT0: ROPN1; NbExp=6; IntAct=EBI-746309, EBI-1378139;
CC       Q92917; Q6FGM0: SH3GL1; NbExp=3; IntAct=EBI-746309, EBI-10173690;
CC       Q92917; Q99961: SH3GL1; NbExp=8; IntAct=EBI-746309, EBI-697911;
CC       Q92917; O60504: SORBS3; NbExp=3; IntAct=EBI-746309, EBI-741237;
CC       Q92917; A6NLX3: SPDYE4; NbExp=3; IntAct=EBI-746309, EBI-12047907;
CC       Q92917; P23193: TCEA1; NbExp=3; IntAct=EBI-746309, EBI-2608271;
CC       Q92917; Q15560: TCEA2; NbExp=7; IntAct=EBI-746309, EBI-710310;
CC       Q92917; Q9NYB0: TERF2IP; NbExp=2; IntAct=EBI-746309, EBI-750109;
CC       Q92917; Q12933: TRAF2; NbExp=7; IntAct=EBI-746309, EBI-355744;
CC       Q92917; P36406: TRIM23; NbExp=4; IntAct=EBI-746309, EBI-740098;
CC       Q92917; P14373: TRIM27; NbExp=3; IntAct=EBI-746309, EBI-719493;
CC       Q92917; Q8N1B4: VPS52; NbExp=3; IntAct=EBI-746309, EBI-2799833;
CC       Q92917; Q9H0C1: ZMYND12; NbExp=3; IntAct=EBI-746309, EBI-12030590;
CC       Q92917; Q9UGI0: ZRANB1; NbExp=3; IntAct=EBI-746309, EBI-527853;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:21880142,
CC       ECO:0000269|PubMed:25296192}.
CC   -!- PTM: Phosphorylation regulates its ability to bind RNA.
CC       {ECO:0000269|PubMed:21880142}.
CC   -!- SIMILARITY: Belongs to the MOS2 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB18640.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U66359; AAB18640.1; ALT_SEQ; mRNA.
DR   EMBL; BC000397; AAH00397.1; -; mRNA.
DR   EMBL; BC003148; AAH03148.1; -; mRNA.
DR   EMBL; AB209806; BAD93043.1; -; mRNA.
DR   CCDS; CCDS35251.1; -.
DR   RefSeq; NP_056513.2; NM_015698.5.
DR   SMR; Q92917; -.
DR   BioGRID; 118086; 75.
DR   IntAct; Q92917; 67.
DR   MINT; Q92917; -.
DR   STRING; 9606.ENSP00000156109; -.
DR   iPTMnet; Q92917; -.
DR   MetOSite; Q92917; -.
DR   PhosphoSitePlus; Q92917; -.
DR   BioMuta; GPKOW; -.
DR   DMDM; 134048659; -.
DR   EPD; Q92917; -.
DR   jPOST; Q92917; -.
DR   MassIVE; Q92917; -.
DR   MaxQB; Q92917; -.
DR   PaxDb; Q92917; -.
DR   PeptideAtlas; Q92917; -.
DR   PRIDE; Q92917; -.
DR   ProteomicsDB; 75602; -.
DR   Antibodypedia; 340; 176 antibodies.
DR   DNASU; 27238; -.
DR   Ensembl; ENST00000156109; ENSP00000156109; ENSG00000068394.
DR   GeneID; 27238; -.
DR   KEGG; hsa:27238; -.
DR   UCSC; uc004dmr.5; human.
DR   CTD; 27238; -.
DR   DisGeNET; 27238; -.
DR   GeneCards; GPKOW; -.
DR   HGNC; HGNC:30677; GPKOW.
DR   HPA; ENSG00000068394; Low tissue specificity.
DR   MalaCards; GPKOW; -.
DR   MIM; 301003; gene.
DR   neXtProt; NX_Q92917; -.
DR   OpenTargets; ENSG00000068394; -.
DR   Orphanet; 2570; Lethal intrauterine growth restriction-cortical malformation-congenital contractures syndrome.
DR   PharmGKB; PA134956055; -.
DR   VEuPathDB; HostDB:ENSG00000068394.10; -.
DR   eggNOG; KOG4315; Eukaryota.
DR   GeneTree; ENSGT00390000015154; -.
DR   HOGENOM; CLU_045183_1_0_1; -.
DR   InParanoid; Q92917; -.
DR   OMA; YYNSKMR; -.
DR   OrthoDB; 1427830at2759; -.
DR   PhylomeDB; Q92917; -.
DR   TreeFam; TF316786; -.
DR   PathwayCommons; Q92917; -.
DR   Reactome; R-HSA-72163; mRNA Splicing - Major Pathway.
DR   BioGRID-ORCS; 27238; 373 hits in 624 CRISPR screens.
DR   GenomeRNAi; 27238; -.
DR   Pharos; Q92917; Tbio.
DR   PRO; PR:Q92917; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q92917; protein.
DR   Bgee; ENSG00000068394; Expressed in muscle of leg and 230 other tissues.
DR   Genevisible; Q92917; HS.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005681; C:spliceosomal complex; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0000398; P:mRNA splicing, via spliceosome; IMP:UniProtKB.
DR   CDD; cd13152; KOW_GPKOW_A; 1.
DR   CDD; cd13153; KOW_GPKOW_B; 1.
DR   InterPro; IPR000467; G_patch_dom.
DR   InterPro; IPR041993; GPKOW_KOW1.
DR   InterPro; IPR041994; GPKOW_KOW2.
DR   InterPro; IPR005824; KOW.
DR   InterPro; IPR026822; Spp2/MOS2_G-patch.
DR   Pfam; PF12656; G-patch_2; 1.
DR   Pfam; PF00467; KOW; 1.
DR   SMART; SM00443; G_patch; 1.
DR   SMART; SM00739; KOW; 2.
DR   PROSITE; PS50174; G_PATCH; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Isopeptide bond; mRNA processing; mRNA splicing; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; RNA-binding; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   CHAIN           2..476
FT                   /note="G-patch domain and KOW motifs-containing protein"
FT                   /id="PRO_0000087559"
FT   DOMAIN          164..210
FT                   /note="G-patch"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00092"
FT   DOMAIN          240..267
FT                   /note="KOW 1"
FT   DOMAIN          415..442
FT                   /note="KOW 2"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         27
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:21880142"
FT   MOD_RES         35
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         42
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         115
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         216
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         316
FT                   /note="Phosphothreonine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:21880142"
FT   MOD_RES         471
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         473
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   CROSSLNK        5
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   MUTAGEN         27
FT                   /note="S->A: Reduced phosphorylation. Significant loss of
FT                   phosphorylation and increased RNA-binding; when associated
FT                   with A-316."
FT                   /evidence="ECO:0000269|PubMed:21880142"
FT   MUTAGEN         176..177
FT                   /note="GW->AA: Significant loss of interaction with DHX16.
FT                   No loss of pre-mRNA splicing activity. Able to suppress the
FT                   splicing defect observed in dominant-negative DHX16 mutant
FT                   expressing cells."
FT                   /evidence="ECO:0000269|PubMed:25296192"
FT   MUTAGEN         259..260
FT                   /note="GK->AA: No loss of interaction with DHX16. Reduced
FT                   pre-mRNA splicing activity. Decreased ability to suppress
FT                   the splicing defect observed in dominant-negative DHX16
FT                   mutant expressing cells."
FT                   /evidence="ECO:0000269|PubMed:25296192"
FT   MUTAGEN         316
FT                   /note="T->A: Reduced phosphorylation. Significant loss of
FT                   phosphorylation and increased RNA-binding; when associated
FT                   with A-27."
FT                   /evidence="ECO:0000269|PubMed:21880142"
FT   CONFLICT        317
FT                   /note="L -> F (in Ref. 3; BAD93043)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   476 AA;  52229 MW;  36F1C5771969897D CRC64;
     MADSKEGVLP LTAASTAPIS FGFTRTSARR RLADSGDGAG PSPEEKDFLK TVEGRELQSV
     KPQEAPKELV IPLIQNGHRR QPPARPPGPS TDTGALADGV VSQAVKELIA ESKKSLEERE
     NAGVDPTLAI PMIQKGCTPS GEGADSEPRA ETVPEEANYE AVPVEAYGLA MLRGMGWKPG
     EGIGRTFNQV VKPRVNSLRP KGLGLGANLT EAQALTPTGP SRMPRPDEEQ EKDKEDQPQG
     LVPGGAVVVL SGPHRGLYGK VEGLDPDNVR AMVRLAVGSR VVTVSEYYLR PVSQQEFDKN
     TLDLRQQNGT ASSRKTLWNQ ELYIQQDNSE RKRKHLPDRQ DGPAAKSEKA APRSQHWLHR
     DLRVRFVDNM YKGGQYYNTK MIIEDVLSPD TCVCRTDEGR VLEGLREDML ETLVPKAEGD
     RVMVVLGPQT GRVGHLLSRD RARSRALVQL PRENQVVELH YDAICQYMGP SDTDDD
//
